Bavarian Nordic stock has delivered a solid 36.1% return over the past three years, while a fresh intrinsic value estimate using a Discounted Cash Flow (DCF) approach indicates the shares trade at a sizeable discount to that model. At the same time, market based multiples look roughly in line with peers, which leaves investors weighing a high value score against a more neutral read from traditional ratios.
-
Over the past three years the share price is up 36.1%, which signals that investors who held Bavarian Nordic through this period have already seen a meaningful gain.
-
The recently announced share buy back program of up to DKK 750 million can support intrinsic value per share, while execution risks around future vaccine demand and capital allocation may limit how much of the DCF upside is eventually realized.
-
Bavarian Nordic screens as a high value case, with the broader checks leaning cheap and a value score of 6 alongside a Discounted Cash Flow (DCF) estimate that sits about 47.5% above the current share price.
The issue now is whether Bavarian Nordic's current price already reflects the recent good news or if the discount to the intrinsic value estimate still leaves meaningful room for long term upside.
Extend your search beyond Bavarian Nordic and compare its valuation gap with a curated set of 272 high quality undervalued stocks that currently screen as potentially mispriced on Simply Wall St.
Is Bavarian Nordic Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model used here projects the cash that Bavarian Nordic could return to shareholders over time and discounts it back to today. On this model, the latest twelve month free cash flow is about DKK 238.1 million. The long term cash flow path is set up as growing in the near term, then easing back to a more modest trend. Taken together, these projections give an estimated intrinsic value of roughly DKK 415.68 per share.
That intrinsic value is about 47.5% above the current share price implied by the model, so Bavarian Nordic appears undervalued on this cash flow view. The recent report of strong H1 2026 results and the new DKK 750 million buyback program help explain why cash flows and capital returns support a higher value than the current market price.
Overall, the DCF work indicates that Bavarian Nordic stock currently looks undervalued relative to its projected cash generation.
Our Discounted Cash Flow (DCF) analysis suggests Bavarian Nordic is undervalued by 47.5%. Track this in your watchlist or portfolio , or discover 272 more high quality undervalued stocks .
Does Bavarian Nordic Look Fairly Valued on Earnings?
The P/E ratio is a useful way to compare what you pay for each unit of Bavarian Nordic earnings against similar biotechs. The stock currently trades on about 10.7x earnings, which is well below the Biotechs industry average of roughly 26.0x and the peer group average of about 23.4x.
A more tailored fair P/E for Bavarian Nordic that factors in its size, margins and risk profile is around 11.3x. That is very close to the current 10.7x level, so the market price lines up closely with what this framework suggests is reasonable and the discount to broader industry multiples does not, on its own, point to a clear mispricing.
On the P/E multiple, Bavarian Nordic stock appears roughly fairly valued compared with what its earnings profile would typically justify.
See what the numbers say about this price — find out in our valuation breakdown.
The Bavarian Nordic Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Bavarian Nordic pick up where the DCF and P/E checks leave off. They spell out which future paths for Bavarian Nordic's growth, margins and earnings would line up with a much higher or lower share price than today on the Community page. Instead of a single output from a model or ratio, they describe the underlying future that figure depends on so you can watch whether those assumptions actually play out over time.
One of the top community narratives on Bavarian Nordic: 18% undervalued
"Reliance on government contracts and a few high-value vaccines makes future revenues vulnerable to shifting spending priorities and competitive pressures."
Read one of the top narratives on Bavarian Nordic
Do you think there's more to the story for Bavarian Nordic? Head over to our Community to see what others are saying!
The Bottom Line
For Bavarian Nordic, the Discounted Cash Flow (DCF) work points to an undervalued stock, while the P/E framework suggests the current price is roughly in line with what comparable earnings would justify. That gap mainly reflects different views on future cash generation versus how the market prices near term growth and risk for similar biotechs today. The key question from here is whether Bavarian Nordic can turn its vaccine pipeline and capital return plans into the cash flows implied in the intrinsic value estimate without being derailed by demand or execution risks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BAVA.CO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
